Nitric oxide differentially regulates pro- and anti-angiogenic markers in DLD-1 colon carcinoma cells  by Hellmuth, Markus et al.
Nitric oxide di¡erentially regulates pro- and anti-angiogenic markers in
DLD-1 colon carcinoma cells
Markus Hellmuth, Jens Paulukat, Raiko Ninic, Josef Pfeilschifter, Heiko Mu«hl
Pharmazentrum Frankfurt, Klinikum der Johann Wolfgang Goethe-Universita«t, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
Received 19 December 2003; revised 11 February 2004; accepted 1 March 2004
First published online 18 March 2004
Edited by Veli-Pekka Lehto
Abstract Inducible nitric oxide (NO) synthase (iNOS) appears
to be a marker of tumor progression in colon carcinogenesis.
Here we investigated e¡ects of NO on selected chemokines that
di¡erentially regulate angiogenesis, namely pro-angiogenic in-
terleukin (IL)-8 as well as tumor-suppressive interferon-induc-
ible protein-10 (IP-10) and monokine induced by interferon-Q
(MIG). These chemokines are expressed by DLD-1 colon car-
cinoma cells after stimulation with IL-1L/interferon-Q. Expres-
sion of IL-8 was markedly upregulated by NO. Moreover, NO
enhanced expression of vascular endothelial growth factor
(VEGF). In contrast, expression of IP-10 and MIG was sup-
pressed by NO. The present data are consistent with previous
observations that link NO to enhanced tumor angiogenesis and
imply that NO-mediated upregulation of IL-8 and VEGF as
well as downregulation of IP-10 and MIG may contribute to
this phenomenon.
1 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Expression of inducible nitric oxide synthase (iNOS) has
been recognized as a marker in human diseases associated
with in£ammation and immunoactivation [1]. iNOS expres-
sion has also been detected in a broad range of human malig-
nancies including colorectal cancer [2]. In these tumors, iNOS
not only is expressed in invading mononuclear cells, but also
in the cancer cells [3]. Moreover, augmented levels of nitro-
tyrosine are detectable in the colon tumor microenvironment
and imply upregulated NOS enzyme activity in vivo [4]. In
vitro, expression of iNOS is induced in human epithelial-like
DLD-1 colon carcinoma cells by incubation with the Th1
cytokine interferon-Q (IFNQ), particularly in combination
with pro-in£ammatory cytokines [5].
Although reports on the function of nitric oxide (NO) in
tumor biology are not entirely uniform, several studies imply
a role for NO in colon carcinogenesis. Notably, NO has been
associated with augmented angiogenesis [2,6] and increased
p53 mutation frequency in colorectal cancer [3]. To further
examine the basis of NO-induced angiogenesis, we analyzed
the in£uence of NO on expression of selected regulators of
angiogenesis that are supposed to be expressed by colon car-
cinoma cells in an in£amed microenvironment. Speci¢cally,
e¡ects of NO on expression of pro-angiogenic interleukin
(IL)-8 [7] and vascular endothelial growth factor (VEGF) [8]
as well as e¡ects on anti-angiogenic interferon-inducible pro-
tein-10 (IP-10) and monokine induced by interferon-Q (MIG)
[7] were investigated.
2. Materials and methods
2.1. Materials
Recombinant human IFNQ and IL-1L were from Pepro Tech Inc.
(Frankfurt, Germany) and Cell Concepts (Umkirch, Germany), re-
spectively. (Z)-1-[2-(2-aminoethyl)-N-(2-ammonioethyl)-amino] dia-
zen-1-ium-1,2-diolate (DETA-NO) was from Alexis Biochemicals
(Gru«nberg, Germany).
2.2. Cultivation of DLD-1 cells
The human colon carcinoma cell line DLD-1 was from the Centre
for Applied Microbiology and Research (Salisbury, UK). Cells were
grown in Dulbecco’s modi¢ed Eagle’s medium (DMEM) supple-
mented with 100 U/ml penicillin, 100 ug/ml streptomycin and 10%
(v/v) heat-inactivated fetal calf serum (FCS) (Gibco BRL, Eggenstein,
Germany). Experiments were performed in the aforementioned cul-
ture medium in the absence of FCS. Unless otherwise stated, DLD-1
cells were preincubated with DETA-NO (1 mM) for 16 h. Thereafter,
IL-1L/IFNQ was added. After another 8 h of incubation, cell-free
supernatants were harvested and cells were lysed for RNA isolation.
Under these conditions DETA-NO did not modulate viability of
DLD-1 cells as detected by lactate-dehydrogenase assay (Boehringer
Mannheim, Mannheim, Germany) (data not shown).
2.3. Determination of mRNA for IL-8 and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) by reverse transcriptase-polymerase
chain reaction (RT-PCR)
Total RNA was isolated using Tri-reagent according to the manu-
facturer’s instructions (Sigma). 1 ug of RNA were used for RT-PCR
(GeneAmp RNA PCR kit using Amplitaq Gold, Perkin-Elmer Corp.,
Weiterstadt, Germany). The following sequences were performed for
PCR: 94‡C for 10 min (one cycle); 94‡C for 1 min, 60‡C for 1 min,
and 72‡C for 2 min (with variable numbers of cycles); ¢nal extension
at 72‡C for 7 min. Sequences of the primers, numbers of cycles, and
length of resulting amplicons: IL-8 (F): 5P-atg act tcc aag ctg gcc gtg
gct-3P, IL-8 (R): 5P-ctc agc cct ctt caa aaa ctt ctc-3P, 28 cycles, 289 bp;
GAPDH (F): 5P-acc aca gtc cat gcc atc ac-3P, GAPDH (R): 5P-tcc acc
acc ctg ttg ctg ta-3P, 23 cycles, 452 bp. Duplicate PCRs without re-
verse transcription were performed and analyzed in parallel in order
to control for possible contaminations of RNA isolates with genomic
DNA. Identity of amplicons was con¢rmed by sequencing (310 Ge-
netic Analyzer, Perkin-Elmer Corp.).
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2.4. Determination of mRNA for VEGF and GAPDH by RNase
protection assay
Assays were performed as previously described [9]. Human VEGF
and GAPDH were cloned by PCR. The cDNA fragments correspond
to nucleotides 347^633 for VEGF and 148^302 for GAPDH, respec-
tively [10].
2.5. Detection of IP-10, MIG, and L-actin mRNA expression by
Northern blot analysis
15 ug of RNA were separated on 1.4% agarose/formaldehyde gels
and transferred to gene screen membranes (NEN Life Science Prod-
ucts, Boston, MA, USA). Filters were hybridized for 16 h at 42‡C
with 32P-labelled cDNA inserts for detection of IP-10 or MIG. The
following primers were used for isolation of human MIG and IP-10
cDNA using activated DLD-1 cells: 5P-gct ggt tct gat tgg agt gc-3P
(for) and 5P-tga cga gaa cgt tga gat ttt c-3P (rev) for MIG; 5P-agt ggc
att caa gga gta cc-3P (for) and 5P-atc ctt gga agc act gca tc-3P (rev) for
IP-10. cDNA probes were labelled with [32P]deoxycytidine triphos-
phate (dCTP) by random priming (Amersham Pharmacia Biotech,
Freiburg, Germany). Stripped blots were rehybridized to the 32P-la-
belled BamHI/SalI cDNA insert from clone pEX 6 coding for human
L-actin [11].
2.6. Detection of cytokines by enzyme-linked immunosorbent assay
(ELISA)
IP-10, IL-8 (Pharmingen, Hamburg, Germany), and VEGF (RpD
Systems, Wiesbaden, Germany) in cell-free culture supernatants were
quanti¢ed by ELISA according to the manufacturers’ instructions.
2.7. Statistics
Data are shown as meansQS.D. and were analyzed by unpaired
Student’s t-test on raw data using Sigma Plot (Jandel Scienti¢c).
3. Results
3.1. NO ampli¢es expression of pro-angiogenic IL-8 and VEGF
in DLD-1 colon carcinoma cells
To further characterize consequences of enhanced NO pro-
duction at the tumor microenvironment, expression of se-
Fig. 1. NO enhances expression and release of IL-8 from DLD-1
colon carcinoma cells. A,B: DLD-1 cells were incubated as unstimu-
lated control or with DETA-NO (1 mM). After 16 h, IL-1L (50 ng/
ml), IFNQ (10 ng/ml) or IL-1L plus IFNQ were added as indicated.
A: After 8 h, release of IL-8 was determined by ELISA. Mean IL-8
concentrationsQ S.D. are shown (n=6). **P6 0.01 compared to un-
stimulated control; ##P6 0.01 compared to stimulation with IL-1L/
IFNQ alone. B: After an additional incubation period of 8 h, ex-
pression of IL-8 was determined by RNase protection assay. One
representative of three independently performed experiments is
shown. C: NO as a single stimulus mediates expression of IL-8.
DLD-1 cells were stimulated with the indicated concentrations of
DETA-NO. After 25 h, IL-8 was determined by ELISA (C). Data
are expressed as mean IL-8 concentrationsQ S.D. (n=6). **P6 0.01
compared to unstimulated control.
Fig. 2. NO mediates induction of VEGF in DLD-1 cells. DLD-1
cells were stimulated for 24 h with DETA-NO at 1 mM (A) or with
DETA-NO at the indicated concentrations (B). Thereafter, release
of VEGF was determined by ELISA (A) and mRNA expression
was evaluated by RNase protection assay (B). Data are expressed as
mean VEGF concentrationsQ S.D. (n=6). *P6 0.05 compared to
unstimulated control.
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lected regulators of angiogenesis were investigated. IL-8 has
been recognized as important pro-angiogenic mediator [7].
Thus, e¡ects of exogenous NO on the production of IL-8
by DLD-1 cells were investigated. As shown in Fig. 1A, IL-
1L potently activated release of IL-8. Coincubation with IL-
1L/IFNQ did not further upregulate IL-8 production. IL-8 was
not inducible by IFNQ alone. Thus, IL-8 is primarily an IL-
1L-dependent gene in DLD-1 cells. The role of NO in regu-
lating gene expression in these cells was investigated by pre-
incubation with the NO donor DETA-NO. We particularly
selected DETA-NO since this donor spontaneously releases
NO with a characteristically long half-life of 16.5^20 h
[12,13]. This slow-releasing NO donor may thus resemble
chronic iNOS activation. DETA-NO signi¢cantly augmented
release of IL-8 by DLD-1. Augmented secretion of IL-8 was
paralleled by upregulation of mRNA steady-state levels (Fig.
1B). NO signi¢cantly increased low level basal release of IL-8
(Fig. 1C) and also expression of mRNA as detected by RT-
PCR analysis (data not shown). In accord with previous data
we con¢rm that DLD-1 cells constitutively produce VEGF
[14]. Basal expression and release of VEGF were upregulated
by coincubation with NO (Fig. 2).
3.2. NO suppresses IL-1L/IFNQ-induced expression of the
anti-angiogenic chemokines IP-10 and MIG
Among the chemokines expressed by IL-1L/IFNQ-activated
DLD-1 colon carcinoma cells are the tumor-suppressive mol-
ecules IP-10 and MIG. In contrast to IL-8, expression of these
two mediators required cellular activation by IFNQ (Fig.
3A,C). In these cells coincubation with IL-1L/IFNQ was nec-
essary to detect a robust IP-10 production within a 8 h in-
cubation period (Fig. 3A). Preincubation of DLD-1 cells with
DETA-NO potently reduced expression of IP-10 (Fig. 3B)
and MIG (Fig. 3C, right panel).
4. Discussion
Induction of iNOS protein and activity has been observed
in colorectal cancer [2,3] and is supposed to be mediated by
pro-in£ammatory cytokines expressed at the tumor site [15^
Fig. 3. NO suppresses IL-1L/IFNQ-induced IP-10 and MIG expression. A,C, left panels: DLD-1 cells were kept as unstimulated control or in-
cubated with IL-1L (50 ng/ml), with IFNQ (10 ng/ml), and with IL-1L/IFNQ. After 8 h, release of IP-10 (A, left panel) and expression of IP-10
mRNA (A, right panel) and expression of MIG mRNA (C, left panel) were determined by ELISA and Northern blot analysis. Mean IP-10
concentrationsQ S.D. (n=4) are shown. **P6 0.01 compared to unstimulated control. One representative of three independently performed
Northern blot experiments is shown. B,C, right panels: DLD-1 cells were incubated as unstimulated control or with DETA-NO (1 mM). After
16 h, IL-1L (50 ng/ml)/IFNQ (10 ng/ml) was added as indicated. Following an additional 8 h incubation period, release of IP-10 (B, left panel)
and expression of IP-10 mRNA (B, right panel) and MIG mRNA (C, right panel) were determined by ELISA and Northern blot analysis.
Mean IP-10 concentrationsQ S.D. (n=6) are shown. **P6 0.01 compared to unstimulated control; #P6 0.05 compared to IL-1L/IFNQ alone.
One representative of three independently performed Northern blot experiments is shown.
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17]. Upregulation of iNOS also has been observed in other
human cancers, among them breast [18] and head and neck
cancer [19]. Cell culture experiments suggest an anti-prolifer-
ative role of NO on colon carcinoma cells [20]. Furthermore,
apoptosis of cancer cells driven by NO in vitro is a well-de-
scribed phenomenon [21]. However, analysis of iNOS in hu-
man tumor tissues and murine tumor models may point to a
di¡erent role of NO in tumor biology. Expression of iNOS in
colon cancer is positively correlated with the frequency of
mutations in the p53 tumor suppressor gene. This implies
that NO provides a signi¢cant selection pressure for non-func-
tional p53, a mechanism that may ultimately promote tumor
growth [3]. It has also been reported that overexpression of
iNOS in DLD-1 cells results in enhanced tumor growth after
injection into nude mice. Tumors derived from these iNOS
overexpressing carcinoma cells appear markedly more vascu-
larized [6]. Notably, expression of iNOS and production of
NO has been recognized as a marker of poor prognosis in
colorectal cancer [22,23].
As angiogenesis is a chief parameter determining tumor
growth, we investigated e¡ects of NO on DLD-1 cells with
respect to expression of four well-documented regulators of
angiogenesis, namely angiogenic VEGF [24] and IL-8 as well
as angiostatic IP-10 and MIG [7]. Due to divergent time ki-
netics (chemokine production: fast; iNOS expression and NO
production much more delayed compared to chemokine pro-
duction) it turned out to be impossible to investigate the
function of endogenously produced NO in this experimental
setting (data not shown). Therefore, in the present study the
slow-releasing NO donor DETA-NO [25] was used in order to
resemble iNOS-dependent high output production of NO in
cancerous tissues. Here, we report that production of IL-8 in
DLD-1 cells is augmented by coincubation with NO. Upreg-
ulation of IL-8 release by NO agrees with reports on human
mesangial cells [26], endothelial cells [27], and monocytic cells
[12]. It is interesting to note that IL-8 not only is as active as
VEGF in mediating angiogenesis [28], but is also a growth
factor for colon carcinoma cells [29]. In accord with previous
data on glioblastoma and hepatocellular carcinoma cells [30],
constitutive production of VEGF was enhanced by NO. Like-
wise, overexpression of iNOS can mediate ampli¢cation of
VEGF [31] and reduced VEGF has been detected in tumors
of iNOS-de¢cient mice [32]. In contrast, expression of the
angiostatic chemokines IP-10 and MIG was suppressed by
NO. A similar e¡ect of NO has been observed in vascular
endothelial cells [33]. These results suggest that NO may be
able to speci¢cally downregulate cellular responses to IFNQ in
DLD-1 cells. This notion concurs with a report that demon-
strates the capability of NO to interfere with activation of
STAT-1 [34], a pivotal component of IFNQ signalling. By
contrast, NO enhances a broad range of signaling pathways
triggered by in£ammatory cytokines like IL-1L and may
thereby evoke ampli¢cation of IL-8 and VEGF expression
[35].
Taken together, NO di¡erentially regulated expression of
modulators of angiogenesis in DLD-1 colon carcinoma cells.
Production of tumor-promoting IL-8 and VEGF was ampli-
¢ed, whereas in the same cells expression of tumorstatic IP-10
and MIG was e⁄ciently downregulated by NO. As IP-10 and
MIG are supposed to be key mediators of IFNQ-mediated
tumor regression [7], this regulatory function of NO may con-
tribute to the phenomenon of tumor promotion by NO. The
present data are in accord with reports on control of colon
carcinogenesis in rodents by blockage of iNOS activity [36]
and further support the concept of iNOS inhibition as a ther-
apeutic strategy for the treatment of human cancer.
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